Previous Article | Next Article 
Infection and Immunity, August 1999, p. 3836-3841, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Cysteine-Rich Region of the Entamoeba
histolytica Adherence Lectin (170-Kilodalton Subunit) Is
Sufficient for High-Affinity Gal/GalNAc-Specific Binding In
Vitro
Dylan R.
Pillai,1
Peter S. K.
Wan,1
Yvonne
C. W.
Yau,1
Jonathan I.
Ravdin,2 and
Kevin C.
Kain*
Division of Infectious Diseases, The Toronto
Hospital and Institute of Medical Science, University of Toronto,
Toronto, Ontario, Canada M5G 2C4,1 and
Department of Medicine, University of Minnesota, Minneapolis,
Minnesota 554552
Received 17 December 1998/Returned for modification 21 January
1999/Accepted 29 April 1999
 |
ABSTRACT |
Adherence of Entamoeba histolytica trophozoites to
colonic mucin, epithelium, and other target cells is mediated by the
amebic Gal/GalNAc lectin. We constructed in vitro expression vectors containing full-length (residues 1 to 1280), cysteine-poor (1 to 353 and 1 to 480), and cysteine-rich (356 to 1143 and 480 to 900) fragments
of the gene encoding the heavy subunit of the adherence lectin,
hgl2. In vitro transcription followed by translation using a nuclease-treated rabbit reticulocyte lysate system was carried out.
Immunoreactivity of in vitro-translated Hgl2 was confirmed by
immunoprecipitation with lectin-specific monoclonal antibodies (MAbs)
1G7 and 8A3, which recognize linear epitopes. Protein disulfide isomerase (PDI) refolding of Hgl2 enhanced immunoreactivity
(P < 0.05) with the conformationally dependent MAb
3F4. Binding of PDI-refolded full-length (P < 0.001)
and cysteine-rich (P = 0.005) Hgl2 to CHO cells was
galactose dependent and competitively inhibited by native hololectin
(50% inhibitory concentration of 39.6 ng/ml). The cysteine-poor region
(1 to 353) did not bind CHO cells. Both full-length (1 to 1280) and
cysteine-rich (356 to 1143) Hgl2 bound the glyconeoconjugate
GalNAc19BSA in a GalNAc-specific manner. The smaller
cysteine-rich fragment (480 to 900) also exhibited GalNAc-specific
binding but to a lesser extent (P < 0.05) than residues 1 to 1280 and 356 to 1143. Neither the cysteine-poor fragment
(1 to 480), luciferase (protein control), nor control translation
reactions (without hgl2 lectin mRNA) bound
GalNAc19BSA. Binding to GalNAc19BSA was shown
to be dependent on the concentration of GalNAc19BSA coated
in each well or 35S-lectin added
(KD = 0.85 ± 0.37 pM). Binding was
competitively inhibited by the terminal GalNAc-containing glycoprotein
asialofetuin (P < 0.005). Taken together, these data
provide direct evidence that the cysteine-rich region of the Gal/GalNAc
lectin heavy subunit contains one or more carbohydrate-binding domains.
 |
INTRODUCTION |
Entamoeba histolytica is
the causative agent of amebiasis. Infection leads to an estimated 40 million to 50 million cases of amebic colitis or liver abscess
annually. Amebiasis is surpassed only by malaria and schistosomiasis as
a leading cause of death caused by parasitic disease (32).
The pathogenesis of E. histolytica infection involves
adherence to colonic mucin (5), cytolysis of host epithelial
and immune effector cells (8, 9, 22), and modulation of host
immune functions including proteolysis of secretory immunoglobulin A
(IgA) (24, 31), complement evasion (26), and
inhibition of macrophage defense mechanisms (3). Adherence
to several cell types is mediated by the Gal/GalNAc-specific lectin,
which is composed of a single membrane-spanning 170-kDa heavy subunit
(13, 30) linked by disulfide bonds to either a 31- or 35-kDa
light subunit (14, 29). The 31-kDa isomer is thought to be
glycosylphosphatidylinositol anchored, the significance of which is
unclear (15). Both the heavy and light subunits are encoded
by multiple genes (15, 21). Interestingly, a homologous Gal/GalNAc lectin is also present and expressed in the morphologically identical but genetically distinct nonpathogenic ameba Entamoeba dispar (20).
The heavy subunit is an immunodominant amebic surface protein and is
recognized by antisera from patients with invasive disease (16). Monoclonal antibodies (MAbs) generated against the
heavy subunit have been reported to both inhibit and enhance adherence, possibly owing to conformational regulation of ligand interaction (19, 28). Epitopes recognized by adherence-inhibitory MAbs map to the cysteine-rich segment (residues 596 to 1082) of the heavy
subunit, suggesting indirectly that the carbohydrate-binding domain(s)
lies within this region (11). Others have suggested that a
sugar-binding domain lies within the pseudorepeat region (436 to 624)
(10). Binding studies using amebic membranes with glyconeoconjugates show that the Gal/GalNAc lectin probably relies on
subsite and subunit multivalency in order to achieve avid adherence (1).
In this study, we used the cDNA encoding hgl2 in order to construct in
vitro expression vectors. Full-length Hgl2 (residues 1 to 1280 [FL
Hgl2]) and cysteine-rich Hgl2 (residues 356 to 1143 [CR1 Hgl2] and
480 to 900 [CR2 Hgl2]) were translated in a cell-free system, shown
to be immunoreactive with lectin heavy subunit-specific MAbs and
protein disulfide isomerase (PDI) refolded into a more native
conformation. Using this approach, we directly demonstrate Gal/GalNAc-inhibitable binding by the cysteine-rich region of the heavy subunit.
 |
MATERIALS AND METHODS |
Strains and culture condition.
Axenic E. histolytica HM1:IMSS (ATCC 30459; American Type Culture
Collection, Rockville, Md.) was grown in TYI-S-33 medium supplemented
with penicillin (100 U/ml) and streptomycin sulfate (100 mg/ml) (Life
Technologies, Gaithersburg, Md.) as defined by Diamond et al.
(6). E. histolytica Gal/GalNAc lectin and antilectin MAbs were obtained as previously described (18,
25). CHO cells were grown in Dulbecco's minimal essential medium
supplemented with 10% fetal calf serum and 100 mg of gentamicin per ml
(all obtained from Life Technologies, Gaithersburg, Md.) in
75-cm2 plastic tissue culture flasks (Corning Costar,
Cambridge, Mass.). Cells were harvested with 0.25% trypsin in
Dulbecco's phosphate-buffered saline (DPBS) without Ca2+
and Mg2+ (Life Technologies).
In vitro expression vectors and constructs.
Oligonucleotides
KK79 (5'-ACGT TCT AGA TTA AAT ATC TTA TTA TTA TGT-3') and KK80 (5'-ACGT
GTC GAC TTA TCC ATT GTA AGT AGC TGC-3') were synthesized so as to
correspond to the 5' and 3' ends of hgl2 (Genbank accession
no. L00636) in order to generate the full-length (residues 1 to 1280)
heavy subunit which contains a portion of the signal peptide. The sense
and antisense oligonucleotides were designed with restriction sites for
XbaI and SalI, respectively. A 3.8-kb fragment
was amplified from HM1:IMSS genomic DNA by using high-fidelity
Taqplus DNA polymerase (Stratagene, La Jolla, Calif.). The
amplified product was digested with XbaI and
SalI, cloned into modified pGEM-4Z (Promega Corp., Madison,
Wis.) containing the avian myeloblastosis virus UTL and SP6 promoter
upstream of the XbaI site (pGEM-4Z-FL). In similar fashion,
the following plasmid constructs were generated: pGEM-4Z-CP (1-353)
[expressing cysteine-poor Hgl2 (residues 1 to 353), designated CP
(1-353) Hgl2], using PCR sense primer KK79 and antisense KK114
(5'-ATG TGG TCC AAG TGA AAC AAG-3'); pDISP-CP (1-480), using sense
primer DP50 (5'-CGC CCG GGA TGA AAT TAT TAT TAT TAA ATA TG) and
antisense primer DP51 (5'-GAC CTG CAG ATT AGC TTT TTG TTT ACA TAC);
pDISP-CR2 (480-900), using sense primer DP48 (5'-CGC CCG GGT GTA AAC
AGA AAG CTA ATT G) and antisense primer DP49 (5'-GAC CTG CAG ATA TGC TTC TTT GTA TGC CTC); and pcDNA3 CR1 (356-1143), generated by restriction digestion of in-frame EcoRI sites at 1070 and
3428 in hgl2. Firefly luciferase mRNA (Promega) was used as
a control for translation experiments. Plasmid DNA was purified from
transformed Escherichia coli DH5
, using QIAfilter columns
(Qiagen, Chatsworth, Calif.). Plasmid constructs were linearized
with XbaI (pcDNA3) or SalI (pGEM-4Z and pDISP)
for in vitro transcription.
In vitro transcription and translation.
SalI- or
XbaI-linearized full-length and cysteine-rich constructs
were phenol-chloroform extracted and ethanol precipitated, followed by
resuspension in diethyl pyrocarbonate-treated water. Linearized plasmid
DNA (100 to 800 ng) was added to in vitro transcription reagents as
recommended by the manufacturer (Promega). T7 or SP6 RNA polymerase
transcription was carried out at 37°C for 1 h. RNA concentration
was approximated by 1% agarose gel electrophoresis. RNA transcript was
added directly to the rabbit reticulocyte lysate system reagents as
outlined by the manufacturer (20a).
Translation was carried out in the presence of
L-[35S]cysteine or
[35S]methionine (ICN Pharmaceuticals, Costa Mesa, Calif.)
for 1.5 h at 30°C. Translation products were analyzed by sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) on a
7.5% gel. Gels were fixed for 30 min in 20% methanol-10% acetic
acid followed by the organic scintillant En3Hance (NEN
Research Products, Boston, Mass.) for 45 min, rinsed for 1 min in
distilled water, dried, and exposed to Hyperfilm (Amersham Life Science).
TCA precipitation of in vitro-translated proteins.
To
determine the efficiency of translation for each transcript, in
vitro-synthesized proteins (2 µl) were added to GF/A glass fiber
filter circles (Fisherbrand, Pittsburgh, Pa.), dried, placed in 5 ml of
scintillation fluid (Cytoscint; ICN), and counted (LS1701; Beckman
Instruments Inc., Mississauga, Ontario, Canada) in order to determine
the total radioactivity per reaction. Similarly, 2 µl of translated
protein was added to 1 N NaOH-2% H2O2 (248 µl) for 10 min at 37°C in order to hydrolyze aminoacyl-tRNAs
present in the lysate. After 10 min of incubation, 1 ml of ice-cold
25% trichloroacetic acid (TCA)-2% Casamino Acids was added (30 min, on ice) to precipitate the synthesized protein. The sample was then
added to a GF/A glass fiber filter circle (prewetted with ice-cold 5%
TCA), washed three times with 3 ml of ice-cold 5% TCA, and rinsed once
with 1 ml of acetone. Filter circles were dried at 75°C for 10 min,
and added to scintillation fluid vials, and counted (total incorporated
radioactivity per reaction). Translation efficiency for each protein
was determined with the following formula: % incorporation = (total incorporated radioactivity per reaction/total radioactivity per
reaction) × 100. These data were used to standardize equivalent
counts of incorporated radioactivity for the various synthesized
proteins used in the binding experiments. The amount of
35S-lectin synthesized was determined based on the specific
activity of the L-[35S]cysteine (1,075 Ci/mmol) or [35S]methionine (1,175 Ci/mmol) incorporated
during in vitro synthesis. The number of cysteine or methionine
residues present in FL Hgl2 (98 cysteines and 19 methionines), CR1 Hgl2
(84 cysteines and 10 methionines), CR2 Hgl2 (46 cysteines and 6 methionines), CP Hgl2 (25 cysteines and 10 methionines), and firefly
luciferase (4 cysteines and 14 methionines) were used to determine
amounts of protein translated for experiments performed with either
L-[35S]cysteine or
[35S]methionine labeling. The procedure outlined here is
described in reference 20a.
Treatment with PDI.
PDI was purchased from Panvera Corp.
(Madison, Wis.). Typically, a 40-µl aliquot of the in
vitro-translated protein was treated with 20 µl of 0.2 mM oxidized
glutathione, 20 µl of 2 mM reduced glutathione, and 20 µl of 20 mg
of PDI per ml in 200 mM sodium phosphate buffer (pH 7.5) at room
temperature for 15 min. For a negative control, additional aliquots of
translated protein were treated with reduced glutathione, oxidized
glutathione, and buffer (no PDI).
Immunoprecipitation of in vitro translation products.
A
panel of MAbs directed against the lectin heavy subunit (25)
was used to immunoprecipitate both full-length and cysteine-rich translation products. Recombinant protein G-Sepharose beads (Zymed, South San Francisco, Calif.) were washed three times in 150 mM NaCl-1
mM EDTA-0.5% Triton X-100-0.5% bovine serum albumin (BSA)-10 mM
Tris buffer (pH 8.0) (NETT-BSA). The beads were then incubated with 5 µg of 1G7 (IgG2b), 3F4 (IgG1), 5B8 (IgG1), 7F4 (IgG2b), 8A3 (IgG1),
8C12 (IgG1), CLB (IgG1), or VM58 (IgG1) for 30 min. Equivalent counts
of in vitro-translated [35S]Cys-labeled full-length and
cysteine-rich Hgl2 were added to the various protein
G-Sepharose-coupled MAbs, incubated for 4 to 6 h at room
temperature, and rotated end over end. The beads were centrifuged
(16,000 × g, 1 min); the supernatant discarded and
then washed in the following sequence: NETT-0.5% BSA, NETT, NETT-0.5% NaCl, NETT. The pelleted beads were added to an equal volume of 1× SDS sample buffer and boiled for 10 min with vortex mixing at 5 min. Following centrifugation (16,000 × g,
1 min), the supernatant was loaded on to a prepoured 7.5%
polyacrylamide gel for SDS-PAGE and analyzed by fluorography as above.
Immunoprecipitation of native lectin heavy subunit.
Trophozoites (109) at stationary phase were harvested
following 3 days of growth in YI-S medium. Trophozoites were washed
three times with PBS and resuspended in 500 µg of Sulfo-NHS-Biotin
(Pierce, Rockford, Ill.) per ml for 30 min at room temperature in order to biotinylate all surface antigens. Cells were then washed three times
with PBS to remove unbound biotin, and crude plasma membranes were
prepared according to the method of Aley et al. (2).
Extracted membranes were solubilized in trophozoite solubilization
buffer as described by Petri and Schnaar (17), with the
exception that 2 mM phenylmethylsulfonyl fluoride (PMSF; Sigma Chemical
Co., St. Louis, Mo.) and 50 µg of
trans-epoxysuccinyl-L-leucylamide(4-guanidino)-butane (E-64; Sigma) per ml were used for protease inhibitors in order to
reduce degradation of the 170-kDa heavy subunit. Solubilized membranes
(100 µg) were added to 20 µg of MAb 1G7, 3F4, or CLB coupled to
protein G-Sepharose beads as described earlier. Immunoprecipitation buffer used was NETT-0.5% BSA containing 50 µg of E-64 per ml and
0.4 mM PMSF. Antibody-coupled beads and solubilized membrane fraction
were rotated end over end overnight at 4°C in immunoprecipitation buffer (NETT-0.5% BSA containing 50 µg of E-64 per ml and 0.4 mM
PMSF). Beads were centrifuged (16,000 × g, 1 min); the
supernatant was discarded and then washed as outlined above. Pelleted
beads were added to an equal volume of 1× SDS sample buffer and boiled for 10 min with vortex mixing at 5 min. Following centrifugation (16,000 × g, 1 min), the supernatant was run on a
prepoured SDS-7.5% polyacrylamide gel and transferred onto
nitrocellulose (Life Technologies). Blots were blocked in 5% milk
protein-Tris-buffered saline containing 0.05% Tween 20 (TTBS) for
2 h at room temperature, incubated with a 1:5,000 dilution of
avidin-horseradish peroxidase in 2% milk protein-TTBS (Bio-Rad
Laboratories, Hercules, Calif.) for 1 h, washed three times with
TTBS for 5 min and once with TBS for 7 min, and developed with enhanced
chemiluminescence ECL reagents (Amersham Life Science).
Flow cytometry.
HM1 trophozoites (105) at
stationary phase were harvested following 3 days of growth in YI-S
medium. Trophozoites were pelleted, washed three times with PBS, and
resuspended in 0.5% BSA-PBS containing a 1:100 dilution of MAb 1G7,
3F4, 7F4, or isotype control CLB for 1 h on ice. Cells were washed
three times with PBS and incubated with a 1:100 dilution of goat
anti-mouse-fluorescein isothiocyanate in 0.5% BSA-PBS (Bio-Rad) for
30 min on ice. Cells were washed three times with PBS and finally
resuspended in 2% paraformaldehyde-PBS until analysis by flow
cytometry (Coulter Epics Elite ESP) for fluorescence intensity.
CHO binding studies.
CHO cells were trypsinized and
resuspended in minimal essential medium, centrifuged (1,000 × g for 3 min), and washed twice in DPBS. The cell pellet was
resuspended in either DPBS, DPBS-55 mM glucose, DPBS-55 mM mannose,
DPBS-55 mM D-galactose, or DPBS-purified native lectin (1, 10, or 50 ng/ml). All sugars were obtained from Sigma-Aldrich
(Oakville, Ontario, Canada). The final suspension of cells was counted
on a hemocytometer, and concentrations were adjusted to 106
cells/ml; 5 × 105 cells were aliquoted into 12- by
75-mm polystyrene culture tubes. PDI-treated in vitro-translated
protein (100,000 cpm; determined as described above) was added and
incubated with the cells at 4°C for 60 min. After incubation, the
cells were washed twice in DPBS, DPBS-sugar, or DPBS-native lectin. The
washed cells were layered onto a 4:1 mixture of silicon oil
(Accumetric, Elizabeth, Ky.) and mineral oil (Sigma-Aldrich) in a
1.5-ml microcentrifuge tube. The cells were pelleted at
9,000 × g for 1 min. The tips of the microcentrifuge
tubes containing the cell pellets were cut off and dropped into 10 ml
of scintillation fluid (CytoScint) and counted. Absolute counts were at
least 30-fold higher than background. All binding experiments were
carried out in duplicate or triplicate, and results are presented as
means ± standard errors (SE) (n = 3).
GalNAc-BSA binding studies.
The glyconeoconjugate
GalNAc19BSA (Sigma-Aldrich) was resuspended in PBS at 1 mg/ml. GalNAc19BSA (50 µg per well) was added to Immulon
2 Removawell strips (Dynatech Laboratories, Inc., Chantilly, Va.) and
incubated at room temperature for 2 h. The unbound
glyconeoconjugate was then pipetted and discarded. Control wells were
coated with 50 µg of BSA (Sigma-Aldrich) in the same way. Equal
counts (100,000 cpm) of 35S-labeled in vitro translated and
PDI-refolded lectin heavy subunit were resuspended in 0.1% BSA-PBS,
added to GalNAc19BSA and BSA (control well) in parallel,
and incubated for 2 h at room temperature. The unbound lectin was
then discarded, and the wells were washed three times with PBS. The
wells were snapped off each of the Removawell strips, added to
scintillation vials (5 ml; CytoScint), and counted (counts per minute,
with <3% error per reading). GalNAc-specific binding was determined
as follows: GalNAc-specific binding (cpm) = lectin bound to
GalNAc19BSA (cpm)
lectin bound to BSA (cpm).
For inhibition experiments, equal amounts of 35S-lectin
were preincubated with asialofetuin (25 or 50 µM) or the irrelevant glycoprotein holotransferrin (50 µM) and incubated for 1 h at room temperature with end-over-end rotation. Lectin and inhibitor were
then added to glyconeoconjugate- or BSA-coated wells and analyzed as
described above. Radiolabeled protein added in each binding experiment
was standardized by trichloroacetic acid (TCA) precipitation. SDS-PAGE
of the same proteins was carried out to further ensure specific
translation. All GalNAc-BSA binding experiments were performed at least
three times in duplicate or triplicate.
Densitometric analysis.
All films were photographed (Gel
Documentation System; U.V.P. Inc., San Gabriel, Calif.) and analyzed
with software by Scion Image (Scion Corp., Frederick, Md.).
 |
RESULTS |
Immunoprecipitation of FL and CR Hgl2.
Both FL and CR
Hgl2 were translated in vitro in a rabbit reticulocyte lysate system.
FL Hgl2 migrated at ~170 kDa, CR1 Hgl2 migrated at ~110 kDa, and
CR2 Hgl2 migrated at ~70 kDa by SDS-PAGE under denaturing and
reducing conditions. To ensure that lectin translation products were
immunoreactive, 35S-labeled FL, CR1, and CR2 Hgl2 were
immunoprecipitated with a panel of antilectin MAbs. Equal amounts of
radiolabeled protein were added to protein G-Sepharose-coupled MAb,
coincubated, and washed, and bound protein was run on a 7.5%
polyacrylamide gel under both reducing and denaturing conditions. FL,
CR1, and CR2 Hgl2 were immunoprecipitated with 1G7 and 8A3 and, to a
lesser extent, with 3F4 and 7F4 (Fig. 1
shows data for CR1 Hgl2). In agreement with previous findings
(12), the strong immunoreactivity of 1G7 and 8A3 with the
translated proteins suggests that they recognize linear epitopes, while
MAb 3F4 and 7F4 are likely conformationally dependent. In support of
this conclusion, unfixed HM1 trophozoites expressing the Gal/GalNAc
lectin were shown to be immunoreactive with 3F4 but not isotype control
MAb CLB (Fig. 2A). Moreover, the heavy
subunit of the lectin was specifically immunoprecipitated by 3F4 under
native conditions, suggesting that 3F4 recognizes the heavy subunit
when conformationally intact on the trophozoite (Fig. 2B). The observed
170-kDa band was confirmed to be the lectin heavy subunit by Western
immunoblotting (data not shown).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 1.
Immunoprecipitation of in vitro-synthesized
35S-labeled CR1 Hgl2. CR1 Hgl2 was immunoprecipitated with
antilectin MAbs 1G7 (IgG2b), 3F4 (IgG1), 7F4 (IgG2b), and 8A3 (IgG1)
and irrelevant isotype VM58 (IgG1).
|
|

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoreactivity of 3F4 with the native lectin heavy
subunit. (a) Indirect immunofluorescence of HM1:IMSS trophozoites by
flow cytometric analysis. Primary antilectin MAbs 1G7, 3F4, and
8A3 (CLB was the isotype control used to measure background) were
monitored by secondary goat anti-mouse-fluorescein
isothiocyanate. Data depict fluorescence intensity on a logarithmic
scale for 104 trophozites from a representative experiment.
(b) Immunoprecipitation of biotinylated native lectin heavy subunit
(170 kDa) from solubilized amebic membranes, using antilectin MAb 3F4
(IgG1) and irrelevant isotype control CLB (IgG1). Immunoprecipitates
were subject to SDS-PAGE on a 7.5% gel, transferred to nitrocellulose,
and probed with avidin-horseradish peroxidase.
|
|
To improve detection of in vitro-translated Hgl2 by putative
conformationally dependent MAb 3F4, translation products were treated
with the folding catalyst PDI in the presence of glutathione redox
buffer. The thioredoxin PDI has been shown to promote native pairing of
cysteines required to refold several proteins (7, 27).
Consistent with proper refolding, PDI-treated FL and CR Hgl2
demonstrated reproducibly improved immunoreactivity with 3F4
(P < 0.05 by one-way analysis of variance
[n = 3], based on densitometric analysis) compared to
no PDI treatment (Fig. 3 shows data for CR1 Hgl2). The same experiment
performed with isotype control MAb CLB showed no difference in
immunoreactivity (Fig. 3).
Furthermore, MAbs 1G7 and 8A3, reported to recognize linear epitopes (12), showed no difference in immunoreactivity
with and without PDI treatment (data not shown).

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 3.
Immunoprecipitation of PDI-treated 35S-CR1
Hgl2. CR1 Hgl2 (110 kDa) was immunoprecipitated with and without PDI
treatment by the antilectin MAb 3F4 (IgG1) and the irrelevant isotype
CLB (IgG1).
|
|
Binding of FL and CR Hgl2 to CHO cells.
CHO binding studies
were performed with PDI-refolded 35S-Hgl2. TCA
precipitation was used to quantitate radiolabel incorporation and
standardize each protein synthesis to ensure that differences in
binding were not due to discrepancies in translation efficiency. Consistent with the established carbohydrate specificity of the amebic
lectin (23), FL and CR1 Hgl2 bound to CHO cells with binding
specifically inhibited (60 ± 4.5%; P < 0.005; t
test) by 55 mM galactose but not by 55 mM glucose or 55 mM mannose. In
contrast, radiolabeled protein outside the cysteine-rich domain (residues 1 to 353) did not exhibit galactose-inhibitable binding. As
further evidence for specificity, native purified hololectin (260 kDa)
significantly competed for binding of FL Hgl2 with a 50% inhibitory
concentration (IC50) of 39.6 ng/ml (Fig.
4).

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 4.
Competitive inhibition of 35S-CR1 Hgl2
binding to CHO cells by native hololectin (IC50 = 39.6 ng/ml). Data are presented as means ± SE for duplicate
determinations.
|
|
Binding of FL and CR Hgl2 to GalNAc-BSA.
To confirm and extend
these findings, 35S-labeled FL, CR1, CR2, and CP (1-480)
Hgl2 were PDI refolded and added to microtiter plate wells coated with
the glyconeoconjugate GalNAc19BSA or with BSA alone. As
with CHO cell experiments, TCA precipitation was used to quantitate
radiolabel incorporation for the various constructs and standardize
each radiolabeled protein for binding studies. GalNAc-specific binding
was observed for FL, CR1, and CR2 Hgl2, but no significant binding was
observed for CP Hgl2, the irrelevant protein luciferase, or control
translation reactions performed in the absence of exogenous mRNA
(Fig. 5a). Results
similar to those in Fig. 5a were obtained for experiments
performed with either L-[35S]cysteine or
[35S]methionine, suggesting that TCA precipitation was an
effective method of standardizing radiolabel incorporation for the
different proteins (data not shown). CR2 Hgl2 exhibited lower maximal
binding (Bmax) (P < 0.05, n = 3) than FL Hgl2 and CR1 Hgl2, which bound equally well to
GalNAc-BSA. Binding of CR1 Hgl2 to GalNAc19BSA was
significantly inhibited by 25 and 50 µM asialofetuin (53.1 and 64.8%
inhibition, respectively) but not by equimolar amounts of an irrelevant
glycoprotein (holotransferrin at 50 µM) (Fig. 5B). Binding of
35S-labeled CR Hgl2 was dependent on the concentration of
GalNAc19BSA coated in each well and was saturable (Fig.
6a). Background binding to BSA was not
dependent on the concentration of BSA coated. Furthermore, the
irrelevant control protein luciferase failed to bind
GalNAc19BSA in concentration-dependent manner (Fig. 6a). To
estimate the affinity of binding, 35S-CR Hgl2 (90.54 mCi/nmol) was added in a dose-dependent manner to GalNAc-BSA and BSA
(background control). Specific binding was determined and the least
squares fit of the data to a rectangular hyperbola was used to
calculate the KD (0.85 ± 0.37 pM) and
Bmax (18,125 ± 2,102 cpm) (Fig. 6b).


View larger version (62K):
[in this window]
[in a new window]
|
FIG. 5.
Binding of 35S-labeled FL, CP (1-480), CR1,
and CR2 Hgl2 to GalNAc19BSA. (a) GalNAc-specific binding
(determined as described in the text) of FL, CP, CR1, and CR2 Hgl2, luc
(LUC), or samples from control translation reaction without lectin mRNA
added. Equivalent amounts of 35S-labeled protein used in
each corresponding binding experiment were analyzed by SDS-PAGE and
fluorography to ensure specific in vitro synthesis (shown below each
corresponding bar). CR2 Hgl2 binds to lower maximal activity than FL or
CR1 Hgl2 (*, P < 0.05). (b) Inhibition of
GalNAc-specific binding of cysteine-rich Hgl2 to
GalNAc19BSA with asialofetuin (ASF) and holotransferrin
(hT) at 25 or 50 µM. Data are means ± SE from three separate
experiments performed in duplicate. Statistical significance was
determined by one-way analysis of variance (*, P < 0.005).
|
|

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 6.
Binding of 35S-CR1 Hgl2 to
GalNAc19BSA. (a) Binding of 35S-labeled protein
(100,000 cpm) as a function of GalNAc19BSA concentration
for CR1 Hgl2 (circles) or luciferase (triangles). Nonspecific binding
of CR Hgl2 to BSA is also shown (squares). (b) Specific binding
(determined as described in the text) of 35S-CR Hgl2 (90.54 mCi/nmol) to 50 µg of GalNAc19BSA as a function of the
amount of radiolabeled lectin added to each well. The line represents
the least squares fit of the data to a rectangular hyperbola with the
KD (0.85 ± 0.37 pM) and
Bmax (18,125 ± 2,103 cpm). Data presented
are means ± SE for duplicate determinations.
|
|
 |
DISCUSSION |
An understanding of the molecular basis for amebic adherence may
provide insight into the pathogenesis of invasive disease and a
possible basis for the design of interventions that would disrupt
amebic attachment and cytolysis. For instance, delineating the
carbohydrate-binding capacity of the E. histolytica
Gal/GalNAc lectin may facilitate the rational design of recombinant
protein or DNA vaccines (33). To date, there has been no
direct evidence supporting the assumption that the heavy subunit of the
Gal/GalNAc lectin contains the carbohydrate-binding domain(s). In this
study, we have localized the carbohydrate-binding domains of the
E. histolytica Gal/GalNAc lectin to CR1 of the heavy
subunit. This is the first direct evidence that the cysteine-rich
region of the 170-kDa subunit is sufficient for high-affinity
carbohydrate binding.
The in vitro-synthesized Gal/GalNAc lectin heavy subunit was
specifically recognized by anti-lectin MAbs that bind linear epitopes
(1G7 and 8A3), in agreement with previous observations that 1G7 and 8A3
recognize bacterially produced recombinant fragments of the 170-kDa
subunit when reduced and denatured (12). PDI treatment of
the translated heavy subunit improves its immunoreactivity with the
putative conformationally-dependent anti-lectin MAb, 3F4, suggesting
that it has been folded into a more native conformation. The folding
catalyst PDI has been previously used to achieve functional native
proteins following in vitro synthesis (7, 27). Binding studies using 35S-labeled FL and CR Hgl2 indicated that
millimolar concentrations of the monosaccharide galactose was able to
specifically inhibit binding to CHO cells. Moreover, purified native
hololectin competed binding of 35S-lectin to CHO cells in a
dose-dependent fashion. The fragment containing residues 1 to 353 failed to bind CHO cells in a galactose-dependent manner. These results
suggested that PDI-refolded FL and CR Hgl2 are functional.
To confirm and extend these observations, a more potent multivalent
ligand was evaluated. Previous studies using glyconeoconjugates have
shown that they bind E. histolytica membranes with high
affinity (KD = 10 ± 3 nM), and this is
likely due to the clustered arrangement of the multiple GalNAc residues
present on the glyconeoconjugate (1).
GalNAc39BSA was able to inhibit binding of E. histolytica membranes to the same radioligand at
200,000-fold-lower concentrations than GalNAc alone (1).
Here we show that in vitro-synthesized FL, CR1, and CR2 Hgl2 bind to
GalNAc19BSA in a GalNAc-specific manner. Equivalent amounts
of radiolabeled firefly luciferase or samples from control translation
reactions (no added lectin mRNA) synthesized in identical fashion did
not bind GalNAc19BSA. Binding of FL and CR1 Hgl2 to the
glyconeoconjugate occurred with the same maximal activity, suggesting
that CR2 Hgl contains all carbohydrate-binding activity. However, the
smaller CR2 fragment bound with lower maximal activity, suggesting that
residues between 356 and 480 and between 900 to 1143 contribute to
high-affinity carbohydrate binding. Binding of CR1 was concentration
dependent, appeared to be saturable, and was specifically inhibited by
asialofetuin. The terminal GalNAc-containing glycoprotein asialofetuin
(IC50 of ~30 µM) binds to E. histolytica
membrane-bound lectin but with lower affinity than glyconeoconjugates
like GalNAc39BSA (IC50 = 0.005 µM)
(1). Additionally, commercial preparations of asialofetuin are often incompletely desialylated and may therefore contribute to
incomplete inhibition by this compound. The binding affinity seen for
CR1 Hgl2 (KD = 0.85 ± 0.37 pM) was similar
to that observed for the native lectin resident on amebic membranes
when bound to mucin (KD = 8.2 × 10
11 M), a naturally occurring glyconeoconjugate found in
the human colon (4). These data are consistent with distant
residues contained within CR1 Hgl2 contributing to high-affinity sugar binding conferred by the Gal/GalNAc lectin and may explain prior conflicting evidence about the location of a carbohydrate-binding domain (10, 11). The experimental strategy presented here provides a useful alternative approach to further delineating the
carbohydrate-binding capacity of the 170-kDa subunit.
 |
ACKNOWLEDGMENTS |
This work was supported by Medical Research Council of Canada
grant MT-12665 (K.C.K.) and National Institutes of Health grant AI
18841 (J.I.R.). K.C.K. is a recipient of a career award from the
Ontario Ministry of Health. D.R.P. is funded by an M.D./Ph.D. studentship from the Medical Research Council of Canada.
We thank William Petri (University of Virginia) for the kind gift of
MAbs 1G7 and 8A3, Cheryl Smith for assistance with flow cytometry, and
Kris Chadee (McGill University) and Ian Crandall (University of
Toronto) for helpful discussion and advice.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Tropical Disease
Unit, The Toronto Hospital, 200 Elizabeth St., EN G-224, Toronto, ON,
Canada M5G 2C4. Phone: (416) 340-3535. Fax: (416) 595-5826. E-mail:
kkain{at}torhosp.toronto.on.ca.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Adler, P.,
S. J. Wood,
Y. C. Lee,
R. T. Lee,
W. A. Petri, Jr., and R. L. Schnaar.
1995.
High affinity binding of the Entamoeba histolytica lectin to polyvalent N-acetylgalactosaminides.
J. Biol. Chem.
270:5164-5171[Abstract/Free Full Text].
|
| 2.
|
Aley, S. B.,
W. A. Scott, and Z. A. Cohn.
1980.
Plasma membrane of Entamoeba histolytica.
J. Exp. Med.
152:391-404[Abstract/Free Full Text].
|
| 3.
|
Campbell, D., and K. Chadee.
1997.
Survival strategies of Entamoeba histolytica: modulation of cell-mediated immune responses.
Parasitol. Today
13:184-189.
|
| 4.
|
Chadee, K.,
M. L. Johnson,
E. Orozco,
W. A. Petri, Jr., and J. I. Ravdin.
1988.
Binding and internalization of rat colonic mucins by the galactose/N-acetyl-D-galactosamine adherence lectin of Entamoeba histolytica.
J. Infect. Dis.
158:398-406[Medline].
|
| 5.
|
Chadee, K.,
W. A. Petri, Jr.,
D. J. Innes, and J. I. Ravdin.
1987.
Rat and human colonic mucins bind to and inhibit adherence lectin of Entamoeba histolytica.
J. Clin. Investig.
80:1245-1254.
|
| 6.
|
Diamond, L. S.,
D. R. Harlow, and C. C. Cunnick.
1978.
A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba.
Trans. R. Soc. Trop. Med. Hyg.
72:431-432[Medline].
|
| 7.
|
Gilbert, H. F.
1997.
Protein disulfide isomerase and assisted protein folding.
J. Biol. Chem.
272:29399-29402[Free Full Text].
|
| 8.
|
Guerrant, R. L.,
J. Brush,
J. I. Ravdin,
J. A. Sullivan, and G. L. Mandell.
1981.
Interaction between Entamoeba histolytica and human polymorphonuclear neutrophils.
J. Infect. Dis.
143:83-93[Medline].
|
| 9.
|
Leippe, M.,
J. Andra, and H. J. Muller-Eberhard.
1994.
Cytolytic and antibacterial activity of synthetic peptides derived from amoebapore, the pore-forming peptide of Entamoeba histolytica.
Proc. Natl. Acad. Sci. USA
91:2602-2606[Abstract/Free Full Text].
|
| 10.
|
Lotter, H.,
T. Zhang,
K. B. Seydel,
S. L. Stanley, Jr., and E. Tannich.
1997.
Identification of an epitope on the Entamoeba histolytica 170-kD lectin conferring antibody-mediated protection against invasive amebiasis.
J. Exp. Med.
185:1793-1801[Abstract/Free Full Text].
|
| 11.
|
Mann, B. J.,
C. Y. Chung,
J. M. Dodson,
L. S. Ashley,
L. L. Braga, and T. L. Snodgrass.
1993.
Neutralizing monoclonal antibody epitopes of the Entamoeba histolytica galactose adhesin map to the cysteine-rich extracellular domain of the 170-kilodalton subunit.
Infect. Immun.
61:1772-1778[Abstract/Free Full Text].
|
| 12.
|
Mann, B. J., and L. A. Lockhart.
1998.
Molecular analysis of the Gal/GalNAc adhesin of Entamoeba histolytica.
J. Eukaryot. Microbiol.
45:13S-16S[Medline].
|
| 13.
|
Mann, B. J.,
B. E. Torian,
T. S. Vedvick, and W. A. Petri, Jr.
1991.
Sequence of a cysteine-rich galactose-specific lectin of Entamoeba histolytica.
Proc. Natl. Acad. Sci. USA
88:3248-3252[Abstract/Free Full Text].
|
| 14.
|
McCoy, J. J.,
B. J. Mann,
T. S. Vedvick,
Y. Pak,
D. B. Heimark, and W. A. Petri, Jr.
1993.
Structural analysis of the light subunit of the Entamoeba histolytica galactose-specific adherence lectin.
J. Biol. Chem.
268:24223-24231[Abstract/Free Full Text].
|
| 15.
|
McCoy, J. J.,
B. J. Mann,
T. S. Vedvick, and W. A. Petri, Jr.
1993.
Sequence analysis of genes encoding the light subunit of the Entamoeba histolytica galactose-specific adhesin.
Mol. Biochem. Parasitol.
61:325-328[Medline].
|
| 16.
|
Petri, W. A., Jr.,
M. P. Joyce,
J. Broman,
R. D. Smith,
C. F. Murphy, and J. I. Ravdin.
1987.
Recognition of the galactose- or N-acetylgalactosamine-binding lectin of Entamoeba histolytica by human immune sera.
Infect. Immun.
55:2327-2331[Abstract/Free Full Text].
|
| 17.
|
Petri, W. A., Jr., and R. L. Schnaar.
1995.
Purification and characterization of galactose- and N-acetylgalactosamine-specific adhesin lectin of Entamoeba histolytica.
Methods Enzymol.
253:98-104[Medline].
|
| 18.
|
Petri, W. A., Jr.,
R. D. Smith,
P. H. Schlesinger,
C. F. Murphy, and J. I. Ravdin.
1987.
Isolation of the galactose-binding lectin that mediates the in vitro adherence of Entamoeba histolytica.
J. Clin. Investig.
80:1238-1244.
|
| 19.
|
Petri, W. A., Jr.,
T. L. Snodgrass,
T. F. Jackson,
V. Gathiram,
A. E. Simjee,
K. Chadee, and M. D. Chapman.
1990.
Monoclonal antibodies directed against the galactose-binding lectin of Entamoeba histolytica enhance adherence.
J. Immunol.
144:4803-4809[Abstract].
|
| 20.
|
Pillai, D. R.,
D. Britten,
J. P. Ackers,
J. I. Ravdin, and K. C. Kain.
1997.
A gene homologous to hgl2 of Entamoeba histolytica is present and expressed in Entamoeba dispar.
Mol. Biochem. Parasitol.
87:101-105[Medline].
|
| 20a.
|
Promega Corp.
1995.
Protocols & applications guide, 2nd ed.
Promega Corp., Madison, Wis.
|
| 21.
|
Purdy, J. E.,
B. J. Mann,
E. C. Shugart, and W. A. Petri, Jr.
1993.
Analysis of the gene family encoding the Entamoeba histolytica galactose-specific adhesin 170-kDa subunit.
Mol. Biochem. Parasitol.
62:53-59[Medline].
|
| 22.
|
Ravdin, J. I.,
B. Y. Croft, and R. L. Guerrant.
1980.
Cytopathogenic mechanisms of Entamoeba histolytica.
J. Exp. Med.
152:377-390[Abstract/Free Full Text].
|
| 23.
|
Ravdin, J. I., and R. L. Guerrant.
1981.
Role of adherence in cytopathogenic mechanisms of Entamoeba histolytica. Study with mammalian tissue culture cells and human erythrocytes.
J. Clin. Investig.
68:1305-1313.
|
| 24.
|
Ravdin, J. I., and B. L. Kelsall.
1994.
Role of mucosal secretory immunity in the development of an amebiasis vaccine.
Am. J. Trop. Med. Hyg.
50:36-41.
|
| 25.
|
Ravdin, J. I.,
W. A. Petri,
C. F. Murphy, and R. D. Smith.
1986.
Production of mouse monoclonal antibodies which inhibit in vitro adherence of Entamoeba histolytica trophozoites.
Infect. Immun.
53:1-5[Abstract/Free Full Text].
|
| 26.
|
Reed, S. L.,
J. G. Curd,
I. Gigli,
F. D. Gillin, and A. I. Braude.
1986.
Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica.
J. Immunol.
136:2265-2270[Abstract].
|
| 27.
|
Ruddon, R. W., and E. Bedows.
1997.
Assisted protein folding.
J. Biol. Chem.
272:3125-3128[Free Full Text].
|
| 28.
|
Saffer, L. D., and W. J. Petri.
1991.
Role of the galactose lectin of Entamoeba histolytica in adherence-dependent killing of mammalian cells.
Infect. Immun.
59:4681-4683[Abstract/Free Full Text].
|
| 29.
|
Tannich, E.,
F. Ebert, and R. D. Horstmann.
1992.
Molecular cloning of cDNA and genomic sequences coding for the 35-kilodalton subunit of the galactose-inhibitable lectin of pathogenic Entamoeba histolytica.
Mol. Biochem. Parasitol.
55:225-227[Medline].
|
| 30.
|
Tannich, E.,
F. Ebert, and R. D. Horstmann.
1991.
Primary structure of the 170-kDa surface lectin of pathogenic Entamoeba histolytica.
Proc. Natl. Acad. Sci. USA
88:1849-1853[Abstract/Free Full Text].
|
| 31.
|
Tannich, E.,
H. Scholze,
R. Nickel, and R. D. Horstmann.
1991.
Homologous cysteine proteinases of pathogenic and nonpathogenic Entamoeba histolytica. Differences in structure and expression.
J. Biol. Chem.
266:4798-4803[Abstract/Free Full Text].
|
| 32.
|
Walsh, J. A.
1986.
Problems in recognition and diagnosis of amebiasis: estimation of the global magnitude of morbidity and mortality.
Rev. Infect. Dis.
8:228-238[Medline].
|
| 33.
|
Zhang, T., and S. L. Stanley, Jr.
1994.
Protection of gerbils from amebic liver abscess by immunization with a recombinant protein derived from the 170-kilodalton surface adhesin of Entamoeba histolytica.
Infect. Immun.
62:2605-2608[Abstract/Free Full Text].
|
Infection and Immunity, August 1999, p. 3836-3841, Vol. 67, No. 8
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Abd-Alla, M. D., Jackson, T. F. G. H., Rogers, T., Reddy, S., Ravdin, J. I.
(2006). Mucosal Immunity to Asymptomatic Entamoeba histolytica and Entamoeba dispar Infection Is Associated with a Peak Intestinal Anti-Lectin Immunoglobulin A Antibody Response. Infect. Immun.
74: 3897-3903
[Abstract]
[Full Text]
-
Abd-Alla, M. D., Jackson, T. F. G. H., Soong, G. C., Mazanec, M., Ravdin, J. I.
(2004). Identification of the Entamoeba histolytica Galactose-Inhibitable Lectin Epitopes Recognized by Human Immunoglobulin A Antibodies following Cure of Amebic Liver Abscess. Infect. Immun.
72: 3974-3980
[Abstract]
[Full Text]
-
Katz, U., Ankri, S., Stolarsky, T., Nuchamowitz, Y., Mirelman, D.
(2002). Entamoeba histolytica Expressing a Dominant Negative N-Truncated Light Subunit of Its Gal-Lectin Are Less Virulent. Mol. Biol. Cell
13: 4256-4265
[Abstract]
[Full Text]
-
Cheng, X.-J., Hughes, M. A., Huston, C. D., Loftus, B., Gilchrist, C. A., Lockhart, L. A., Ghosh, S., Miller-Sims, V., Mann, B. J., Petri, W. A. Jr., Tachibana, H.
(2001). Intermediate Subunit of the Gal/GalNAc Lectin of Entamoeba histolytica Is a Member of a Gene Family Containing Multiple CXXC Sequence Motifs. Infect. Immun.
69: 5892-5898
[Abstract]
[Full Text]